COHEN CHARLES J. 4
4 · Xenon Pharmaceuticals Inc. · Filed Dec 13, 2018
Insider Transaction Report
Form 4
COHEN CHARLES J.
VP, Biology
Transactions
- Exercise/Conversion
Common Shares
2018-12-11$3.07/sh+4,115$12,633→ 8,194 total - Tax Payment
Common Shares
2018-12-11$7.00/sh−1,644$11,508→ 6,550 total - Exercise/Conversion
Stock Option (Right to Buy)
2018-12-11−4,115→ 0 totalExercise: $3.07Exp: 2018-12-31→ Common Shares (4,115 underlying)
Footnotes (4)
- [F1]The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.
- [F2]Represents the closing price of the Company's common shares in U.S. dollars on December 10, 2018, converted to a Canadian dollar amount for purposes of net settlementment calculations.
- [F3]The shares subject to the option fully vested on December 31, 2012.
- [F4]The Company withheld the number of shares set forth above pursuant to a net settlement permitted under the terms of a lock-up agreement executed by the Reporting Person in favor of the underwriters of the Company's public offering in September 2018. No shares were sold by the Reporting Person in connection with the exercise and the common shares issued as a result of the exercise are subject to the terms of the lock-up agreement.